AGIL FA

Drug Profile

AGIL FA

Alternative Names: AGIL-FA

Latest Information Update: 04 Aug 2016

Price : $50

At a glance

  • Originator Agilis Biotherapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia

Most Recent Events

  • 02 Aug 2016 AGIL FA receives Orphan Drug status for Friedreich's ataxia in USA
  • 18 Feb 2016 Preclinical trials in Friedreich's ataxia in USA
  • 18 Feb 2016 Agilis andWaisman agree to co-develop AGIL FA in USA for Friedreich’s ataxia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top